GSK/Corixa Bexxar user fee extended
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA extends the review period for GlaxoSmithKline/Corixa's Bexxar by three months, to Aug. 1, to review additional safety data. Corixa submitted safety data in early April from an additional 375 non-Hodgkin's lymphoma patients. The data was requested by FDA after the Dec. 17 Oncologic Drugs Advisory Committee review of the tositumomab BLA. "The overall safety profile of Bexxar was not altered by the inclusion of this additional data," Corixa maintains. "A majority of the steps required for approval already have been completed," the firm notes, including satisfactory pre-approval manufacturing inspections, "agreement on several elements of post approval studies," submission of secondary draft labeling, and "completion and submission of information and procedures for drug ordering, dose preparation, dosimetry methods and dose administration." The companies remain in discussion with FDA regarding labeling and postmarketing commitment
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.